A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma

NCT02754362 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Due to personnel changes / departure of Dr. Chi.

Conditions

Glioblastoma
Glioma

Interventions

DRUG: Bevacizumab
BIOLOGICAL: Peptide Vaccine
DRUG: Poly-ICLC as immune adjuvant
DRUG: Keyhole limpet hemocyanin (KLH)

Sponsor

NYU Langone Health

Collaborators

[object Object]